December 1, 2016 - By Nellie Frank · 0 Comments
Dec 1 is a negative day so far for BioShares Biotechnology Clinical Trials (NASDAQ:BBC) as the ETF is active during the day after losing 2.77% to hit $18.14 per share. The exchange traded fund has 20.05M net assets and 2.75% volatility this month.
Over the course of the day shares traded hands, as compared to an average volume of 11,600 over the last 30 days for BioShares Biotechnology Clinical Trials (NASDAQ:BBC).
The ETF is -32.38% of its 52-Week High and 35.06% of its low, and is currently having ATR of 0.74. This year’s performance is -25.34% while this quarter’s performance is 2.78%.
The ETF’s YTD performance is 0%, the 1 year is 0% and the 3 year is 0%.
More notable recent BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) news were published by: Etftrends.com which released: “Biotech ETFs Will Enjoy a More Favorable Environment” on November 29, 2016, also Etftrends.com with their article: “Will Trump Make Biotech ETFs Great Again?” published on November 28, 2016, Etftrends.com published: “Reasons to bet on new Breed Biotech ETFs” on April 17, 2015. More interesting news about BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) were released by: Etftrends.com and their article: “Silver Lining for Biotechnology ETFs After Pfizer Calls off Allergan Deal” published on April 06, 2016 as well as Seekingalpha.com‘s news article titled: “Bioshares New Equal Weight ETFs Offer Diversification And Growth” with publication date: December 22, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank